Pathways of complement activation in glomerulonephritis  by Holland, Nancy H. et al.
Kidney International, Vol. 1 (1972), p. 106—114
Pathways of complement activation in glomerulonephritis
NANCY H. HOLLAND, MARIA M. E. DE BRACCO, and CHARLES L. CHRISTIAN
Department of Pediatrics, University of Kentucky School of Medicine, Lexington, Kentucky, and the
Hospitalfor Special Surgery, Cornell University College of Medicine, New York, New York
Pathways of complement activation in glomerulonephritis.
Systemic lupus erythematosus and hypocomplementemic glom-
erulonephritis are characterized, by depressed CH50 and C 3
levels, but the complement profiles in these two diseases
show marked differences. Measurement of hemolytic activity
of Cl, C4 and C2 and of protein concentrations by radial
immunodiffusion of Clq, Cis, Cl inhibitor, C4 and C3 again
showed depression of all complement components in systemic
lupus erythematosus as in experimental immune complex disease
but selective lowering of CH50 and C3 in hypocomplementemic
glomerulonephritis. Suppressive therapy in systemic lupus
erythematosus was accompanied by clinical improvement and
a rise of the complement component levels to normal whereas
depressed complement and C3 levels persisted after similar
courses of therapy and during symptomatic remissions of
hypocomplementemic glomerulonephritis. The ratio of Cl
inhibitor/Cl was elevated in systemic lupus erythematosus and
normal in hypocomplementemic glomerulonephritis.
The return of complement components to normal with im-
munosuppressive therapy and the elevation of the Cl inhibitor/Cl
ratio in systemic lupus erythematosus are in accord with the
activation of complement by immune complexes. In hypo-
complementemic glomerulonephritis the persistence of low
levels of complement with immunosuppressive therapy and the
normal Cl inhibitor/Cl ratio suggest that the activation of
complement in this disease is not by immune complexes and the
conventional pathway.
One child with hypocomplementemic glomerulonephritis had
an unusual C2-deficiency, probably on a congenital basis, in
addition to the depression of CH50 and C3 typical of this disease.
The possible relationship of congenital complement abnormalities
to the development of glomerulonephritis deserves further
consideration.
Cheminement des react ions de l'activation du complement
dons Ia glomérulonéphrite. Le lupus erythémateux disséminé
et Ia glomérulonéphrite avec hypocomplémentémie se carac-
térisent par un abaisscment des taux de CH50 et de C 3, bien
que les profils du complement présentent une notable diffé-
rence dans ces deux maladies. La mesure de l'activité hémo-
lytique de Cl, C4 et C2 ainsi que Ia mesure des concentra-
tions protéiniques par immunodiffusion radiaire de Clq, de
Cls, de l'inhibiteur Cl, de C4 et de C3 montrent un abaissement
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de toutes les composantes du complement dans le lupus érythéma-
teux dissiminé, comme d'ailleurs dans les maladies immunologi-
ques expérimentales. Cependant, une diminution selective de
CH50 et de C3 fut observée dans Ia glomérulonéphrite avec
hypocomplémentémie. Le traitement a l'aide d'immunosuppres-
seurs dans Ic lupus érythémateux dissiminé s'est traduit par une
amelioration clinique et une normalisation des composantes du
complement. Par contre, Ia diminution des taux de complement
et de C3 persista durant Ic traitement par immunosuppresseurs
et durant les remissions symptomatiques de Ia glomerulonephrite
avec hypocomplementémie. Le rapport de l'inhibiteur Cl/Cl
était élevé dans le lupus érythemateux dissiminé, mais normal
dans Ia glomerulonephrite avec hypocomplémentemie.
La normalisation des composantes du complement lors du
traitement par immunosuppresseurs ainsi que l'élévation du
rapport inhibiteur Cl/Cl dans Ic lupus Crythémateux dissiminé
correspondent a une activation du complement par des complexes
immuns. La persistance de taux abaissés du complement et le
rapport normal de I'inhibiteur Cl/Cl notes au cours du traite-
ment par immunosuppresseurs dans Ia glomerulonéphrite avec
hypocomplémentémie suggèrent que l'activation du complement
dans cette maladie ne depend pas de complexes immuns et ne
suit pas le cheminement normal des reactions d'activation du
complement.
Nous avons note qu'un enfant atteint de glomerulonéphrite
avec hypocomplémentémie présentait une déficience inhabituelle
en C2, anomalie probablement d'origine congenitale, en plus de
l'abaissement de CH50 et de C3 qui sont observes de facon
caractéristique dans cette maladie. La possibilité qu'il existe une
relation entre les anomalies congénitales du complement et
l'apparition d'une glomerulonéphrite mérite de retenir l'attention.
Depression of serum complement and the deposition
of complement and immune globulin on glomerular
basement membrane has been interpreted as evidence
of an immune etiology of glomerulonephritis [1, 2, 3].
Activation of the complement cascade by antibody to
glomerular basement membrane or by immune com-
plexes leads to the release of biologically active frag-
ments from C3 and C5 which induce local cellular
injury [4]. Experimentally, the activation of comple-
ment by antigen-antibody reactions, both in vivo and
in vitro, results in consumption of each of the 11
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complement proteins in sequence from Clq through
C9 [5]. Of human diseases with low serum complement
levels, the profile in systemic lupus erythematosus
shows depression of Cl—9 as expected in an immune
complex disease. The profile in hypocomplementemic
glomerulonephritis [6, 7] shows sparing of the early
complement components and depression of C3 through
C9 [5, 8]. The pattern suggests that activation of
complement in this disease is not through the classical
pathway after the binding of Clq to antibody, but by
a recently described alternate pathway of complement
activation through a serum beta-globulin, C3 pro-
activator [9].
Serial complement profiles in children with systemic
lupus erythematosus and hypocomplementemic gb-
merulonephritis were compared for evidence of comple-
ment activation by the classical pathway or through
C3 proactivator and the second pathway. Measure-
ments were made by hemolytic assay for functional
activity, and by radial immunodiffusion for the
protein concentration of the complement components.
In systemic lupus erythematosus, the rise in component
titers to normal with suppressive therapy and the
increase in the ratio of Cl inhibitor to Cis (evidence
of immune complex activation of Cl) suggests that
complement is utilized in the classical pathway. In
hypocomplementemic glomerulonephritis, persistent
depression of C3 and CH50 during suppressive therapy
and the normal ratio of Cl inhibitor to Cbs support
the thesis that C is consumed in the alternate pathway.
One child with hypocomplementemic glomerulone-
phritis showed marked depression of C2 as well as C3
but normal or elevated levels of Cl and C4. Levels of
C2 were not as low as those seen in hereditary C2-
deficiency [10], but the presence of decreased C2 in a
healthy sibling indicated that the deficiency was
probably not related to consumption.
Clinical MateriaJ
Serial studies were done on sera from four females,
ages ten to fourteen, with systemic lupus erythematosus
and three females, ages six to twelve years, with hypo-
complementemic glomerulonephritis. Two of the four
with systemic lupus erythematosus, Cases I and 2,
were studied within three weeks of the onset of
symptoms and they were followed during the initial
period of steroid therapy. Fever, rash and arthralgias
preceded evidence of biopsy-proven glomerulonephri-
tis. Case 3 was first examined during an exacerbation
of fever, arthritis and carditis for which she had been
treated sporadically for three years. Case 4 had been
treated for central nervous system disease and glome-
rulonephritis with a variety of immunosuppressive
agents for three years, and she was asymptomatic
when first evaluated.
The three females with hypocomplementemic gb-
merubonephritis were asymptomatic during the period
of observation. Minimal proteinuria or microscopic
hematuria were the only signs of renal disease. Two
children (Cases 5 and 6) with membranoproliferative
glomerulonephritis on renal biopsy had completed
courses of therapy with combined cyclophosphamide
and prednisolone when first tested. Prednisolone was
tapered during the period of observation. Case 7 had
proliferative glomerulonephritis on initial biopsy and
mild membranoproliferative glomerulonephritis on
repeat biopsy one year later. Her only treatment was
a two week course of prednisone and heparin three
months before referral. Control children were patients
on the pediatric wards and in the renal clinic of New
York Hospital, and they represented a variety of
diseases such as idiopathic nephrosis, familial nephritis,
healed acute gbomerulonephritis and recurrent hemat-
uria.
Methods
Fresh blood specimens were allowed to clot at
room temperature for one hour or less and the serum
was stored at — 70° C until used. Sheep erythrocytes
collected in Alsevers solution were washed in EDTA
buffer, 0.01 M, pH 7.4, and reacted with commercial
sheep hemolysin, 1/1500 (Baltimore Biological Labor-
atories, Baltimore, Maryland). Functionally pure C2
was prepared by the method of Nelson et al [10].
Buffers used were: 1) veronal-buffered saline (0.1 5F/2,
pH 7.5) with 0.1% gelatin, calcium 1.5x 104M, and
magnesium 1.0 x l0 M; 2) veronal-buffered saline
(0.075 T'/2, pH 7.5) containing dextrose 2.5%, gelatin
0.1%, calcium 1.5x 104M, and magnesium 0.5x
10 M (designated DGVB); 3) EDTA buffer, 0.01 M,
was prepared by diluting stock EDTA (pH 7.5, 0.10 M),
and it contained 0.1 % gelatin. Hemolytic complement
titers (CH50) were measured by the micro-method of
Kent and Fife [11]. The normal range by this method
is 150 to 250 units. Cl titrations were done by a
modification of the method of Borsos and Rapp [12].
After reacting the erythrocyte-intermediate EAC4gp
with serum dilutions to form EAClhu4gp, the cells
were washed with DGVB and then incubated two
hours at 30° C to allow complete activation of Cl.
Then the EACIhU4gp were reacted with functionally
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pure C2 and guinea pig serum in EDTA buffer in
excess as in the original method. C4 assays were
performed by the method of Ruddy and Austen [13],
and C2 titers were measured by the method of Ruddy
et al [14]. Radial immunodiffusion measurements of
serum protein concentrations of Clq, Cis, Cl-in-
hibitor, C3 and C4 were done by the method of Man-
ci, Carbonara, and Heremans [15]. Antisera were
prepared by injecting rabbits or goats with purified
preparations of Clq [16] and Cls [17]. Antisera
against Cl-inhibitor and C4 were prepared by injecting
specific antigen-antibody precipitates into the same
animal species donating the antibody [l8].1 Anti-C3
was prepared by the method of Mardiney and Muller-
Eberhard [19]. Concentrations of Clq and C4 were
expressed as g/ml, C3 as mg/l00 ml, and Cls and
Cl-inhibitor as percent of a normal sera pool.
1 Antisera against Cl-inhibitor and C4 were kindly provided
by Drs. Fred Rosen and Peter Schur, respectively.
The effect of immune complexes on complement
components and Cl-inhibitor in normal serum was
studied in vitro. One milliliter of normal human serum
was added to washed preformed BSA-anti-BSA
complexes prepared at equivalence containing approxi-
mately 1.0 mg of antibody protein. Residual Clq,
Cls, C3, and Cl-inhibitor protein concentrations
were measured in the supernatant after 60 mm at
37° C.
Anti-DNA antibodies were demonstrated by the
Farr technique [20]. Tests for an inhibitor or inactivator
of C2 or C3 in the serum of the C2-deficient child
(Case 7) were done by observing the effect of her
serum on normal serum titers. To test for C2-inactiva-
tion, the C2-deficient serum was incubated with an
equal volume of normal serum for 30 mm at 30° C,
and the titer was compared with a normal control that
had been incubated with buffer. Test for C3-inactiva-
tion was made by comparing the C3—9 hemolytic
activity of guinea pig serum, normal human serum and
Table 1
Hemolytic Assay of complement components in normal adults, control children and children with systemic lupus
erythematosus and hypocomplementemic glomerulonephritis
CH50
Units
Cl
SFU
C4
SFU
C2
SF1]
Normal adults
No. 9 6 9 6
Range 156—226 58,000—300,00 110,000—290,000 1208—2060
Mean 180 220,000 214,000 1330
Control children
No. 23 9 13 10
Range 137—284 170,000—230,000 57,000—260,000 830—2025
Mean 226 198,000 133,000 1590
15.4
SLEa
1 50 800 490 64
2 50 30,000 490 47
3 109 79,000 32,000 890
4 164 200,000 210,000 1110
HGNa
1 133 109,000 140,000 945
2 95 170,000 166,000 954
3 70 180,000 160,000 42
a SLE =systemic lupus erythematosus; HGN = hypocomplementemic glomerulonephritis. Titers represented are those observed
initially.
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normal human serum plus the C2-deficient serum
after incubation at 370 C for 30 mm.
Kidney biopsies (done on all patients with the
exception of Case 4) were processed and examined in
the Department of Pathology, Cornell University
Medical College. Fluorescent antibody studies were
done with labeled rabbit antiserum to IgG, beta-1C-
globulin and fibrinogen. Rabbit antiserum to pro-
perdin, kindly provided by Dr. John Boyer, was
reacted with the histological section from Case 7 and
subsequently with fluorescein-labeled antibody to
rabbit gamma globulin.
Results
Complement profile. Complement profiles on single
specimens from normal adults, control children and
the children with systemic lupus erythematosus and
hypocomplementemic glomerulonephritis confirmed
previous reports of uniform depression of complement
components in active systemic lupus erythematosus,
300
CH 50200
units 100
Case 1. 10 yrs 9; fever, arthralgia, rash
and of selective depression of C3 and terminal com-
ponents [5, 8] in hypocomplementemic glomerulone-
phritis (Table 1). Only one child with lupus (Case 4),
who was completely asymptomatic after treatment,
had normal values for CH50 and for complement
components. An unexpected finding was the marked
C2-deficiency in a child with hypocomplementemic
glomerulonephritis (Case 7). The higher values for
CH50 and components in the control children compared
to normal adults probably reflects a non-specific
response to inflammation in these hospitalized or
clinic patients.
Serial determinations of the complement profile in
patients with systemic lupus erythematosus during
initial therapy with prednisolone showed significant
rises in CH50 and in Cl, C4 and C2 hemolytic titers
(Fig. 1). As steroid therapy was changed to an alternate
day schedule or tapered, the titers gradually fell. Serum
protein concentrations of Clq, Cis, C4 and C3
similarly rose to normal levels during therapy (Table 2).
Decreased ability of serum to bind DNA by the Farr
Case 2 12 yrs 9; fever, arthralgia, rash
0
3
2
SFU x 105/ml 1
0
3
C4 2
SFU X 105/ml 1
C2
SFU X 103/ml
0
3
2
0
% DNA Binding
Fig. 1. Hemolytic titrations of whole complement (CH50), Cl, C4 and C2 and measurements of anti-DNA antibodies in two
patients with systemic lupus erythematosus. The shaded zones indicate the range of C values in control sera.
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Table 2
Serum protein concentration in systemic lupus erythematosus and hypocomplementemie glomerulonephritis
Pt. Date Clq
jig/mi
Cis
% Normal
C1-Inh
% Normal
C 4
jig/mi
C 3
mg/lOO ml
Normala 150—210 72—110 100 390—654 105-448
SLE
1 11/6/70
12/9/70
4/22/71
<18
101
165
22.5
81
134
55
98
100
35
135
270
29
74
125
2 11/9/70
2/11/71
5/6/71
67
145
103
36
58
64
108
200
97.5
175
416
242
88
170
100
3
4
10/1/70
1/19/71
2/23/71
4/27/71
55
120
185
185
80
89
100
92
250
155
155
155
263
—
400
—
73
90
165
172
HGN
5 9/3/70
4/1/71
150
220
86
172
146 603 60
43
6 9/3/70
2/16/71
130
140
120
70
86
—
362
—
50
35
7 9/25/70
2/11/70
230
230
164
133
146
—
624
—
42
10
a Range in 34 normal adults.
test was noted concurrent with the rise in complement.
In another child (Case 3) an increase in the dosage of
prednisolone sufficient to control symptoms resulted
in a rise in the titers and protein concentrations of
complement components. The initial complement
profile was normal in the child who received prolonged
antimetabolite therapy, and it remained normal in the
absence of therapy. All children were asymptomatic
when their complement profiles were normal.
On the other hand, in hypocomplementemic gb-
merubonephritis, serum CH50 and C3 concentrations
remained abnormally low during completely asympto-
matic periods (Fig. 2). Two patients were completing
prolonged courses of therapy with prednisolone or
combined prednisolone and cyclophosphamide (Cases
5 and 6) at the time of initial testing. In addition to
low CH50 and C3 levels, the third patient (Case 7)
showed depressed C2 levels in every specimen. Hemo-
lytic titers for Cl and C4 and the protein concentra-
tion of the early components measured by radial
complementemic glomerulonephritis. Tests for inhibi-
tion of C2 and C3 activity in the C2-deficient serum
showed no evidence of inactivation of either compo-
nent.
Spec jfic activity of Cl and the Cl-inhibitor/Cl ratio.
In systemic lupus erythematosus, depression of the
serum protein levels for the Cl-subunits, Clq and Cis,
was not as marked as for the hemolytic activity of Cl.
Thus, the functional activity of Cl, the specific activity,
was diminished as compared to normal serum. In
hypocomplementemic glomerubonephritis, the absolute
value for Cl hemolytic activity, the protein concentra-
tions of Clq and Cis and the specific activity were
normal (Table 2 and 3).
The absolute values for Cl-inhibitor were low,
normal, or increased during the active phase of systemic
lupus erythematosus but the ratio of inhibitor to Cl
was elevated in all patients with systemic lupus erythe-
matosus. Normal ratios were found in the children with
immunodiffusion were repeatedly normal in hypo- hypocomplementemic glomerulonephritis.
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CH 50
units
SFU
SFU
SFU
% DNA Binding
Asymptomatic
Prednisolone
40 mg qodL L,
I I I I I
AS OND J FM
Asymptomatic
[l225m qod
I IASONDJ F
14.4
Asymptomatic
Biopsy
M-PGN
4,
I I I ISONDJ FMAM
Months
Fig. 2. Hemolytic titrations of whole complement (CH50), Cl, C4 and C2 in three patients with hypocomplementemic nephritis.
The shaded zones indicate the range of C values in control sera.
Effect of immune complexes on component protein
concentration. The results of incubating immune
complexes with normal serum, shown in Table 4,
demonstrated that 70% of the Clq, 57% of the Cis,
15°/o of the C4, and 25% of the C3 initial protein
concentration was removed by this treatment. On the
other hand, Cl-inhibitor protein concentration re-
mained unchanged. This led to an increased Cl-
inhibitor/C 1 ratio in the supernatant as a consequence
of complement activation by immune complexes.
Anti-DNA antibodies. The percent of DNA-binding
by the Farr technique [20] was elevated in active
systemic lupus erythematosus, especially when comple-
ment titers were depressed, but it fell during immuno-
suppressive therapy or clinical remission (Fig. 1).
Histology. Renal biopsies of subjects with systemic
lupus erythematosus showed glornerular proliferation
and membrane thickening compatible with the diag-
nosis of systemic lupus erythematosus. The three
patients with hypocomplementemic glomerulonephri-
tis had membranoproliferative lesions as described
previously [7], with lobular accentuation, mesangial
stalk thickening and hypercellularity, and basement
membrane splitting. The changes were irregular in
Case 6 and severe in Case 5. Fluorescent antibody
staining was done on biopsies from three children.
In systemic lupus erythematosus (Case 1), lgG and
C3 were deposited on the glomerular basement mem-
brane in a typical granular pattern. In hypocomple-
mentemic glomerulonephritis, both biopsy specimens
— Case7 6yrs9
S •
ND 29.1
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were .positive for granular deposits of C3 on the gb-
merular basement membrane. Case 5 showed a posi-
tive glomerular stain for IgG and fibrinogen. Case 7
exhibited quantitatively little staining for JgG and it
Table 3
Cl hemolytic activity
Case
No.
Date Cl, Specific activity Ratio
Cl Inh/Cls
C1/Clq CI/Cis
1
Systemic hipus erythematosus
11-6-70 44 36 2.44
2-8-71 475 770 1.20
5-20-71 909 404 1.20
2 11-9-70 435 830 3.10
2-11-71 700 2500 3.40
5-6-71 614 980 1.55
3 10-1-70 1450 1000 3.10
1-19-71 1330 1800 1.74
4 2-23-71 1080 2000 1.60
4-27-71 970 1950 1.70
Normal 1000—1400 1500—2000 0.7—I .20
5
Hypocomplementemic glomerulonephritis
9-3-70 533 930 1.00
4-1-70 1270 1760
6 9-3-70 1306 1416 0.71
2-16-71 1000 2000
7 9-3-70 770 1100 0.90
12-17-70 784 1280
Normal 10000-1400 1500-2000 0.7—I .20
a Specific activity hemolytic units/immunochemical concen-
tration of CIq or Cis.
was negative for 1gM, IgA and fibrinogen. Properdin
was demonstrated diffusely in a granular pattern on
the glomerular basement membrane and mesangium.
The authors have not had extensive experience with
the anti-properdin reagent — the antiserum was
identical to that used in immunofluorescent studies of
renal glomeruli by Westberg et al [29].
Discussion
The present observations, which confirm previously
reported differences in the complement profiles of
patients with systemic lupus erythematosus and hypo-
complementemic glomerulonephritis, are based on in
vitro studies of the complement components in sera.
Such data must be viewed in the light of several
variables: different rates of synthesis, existence of
functionally aberrant molecules, presence of inhibitors
and variable pathways of activation (including immuno-
logical reactions and the action of enzymes generated
by the clotting system or released from lysosomes).
Theoretically, the sparing of early components in
hypocomplementemic glomerulonephritis might result
from efficient usage of these components via the
conventional pathway or from a different mechanism
of complement activation. 1mm unofl uorescent studies
of kidney biopsies showing granular deposits IgG,
Clq and C3 on the glomerular basement membrane
are compatible with efficient utilization of early
components subsequent to immune complex activa-
tion. However a number of studies have demonstrated
that C3 and the terminal components can be activated
by lipopolysaccharides [21], zymosan [5], cobra venom
[22] and by pseudoglobulins in the serum of patients
with hypocomplementemic glomerulonephritis [23,
24, 25]. Recently an alternate pathway for the activa-
tion of C3—9 has been described involving the activa-
tion of C3-proactivator from its inactive precursor
Table 4
Depletion of complement components of normal human serum after incubation with BSA-anti-BSA complexesa
Component Clq
pg/mi
Cis
% Normal
C4
pg/mi
C3
mg/mi
Cl-Inh
% Norma!
Initial Concentration 150 72.5 384 1.22 75.8
Final Concentration 45 31.2 286 0.925 75.8
a One ml of normal human serum was added to washed preformed BSA-anti-BSA complexes (1.0mg antibody protein) at equivalence,
incubated for one hour at 370 C and centrifuged. Protein concentration of each subunit or component was assayed by radial immuno-
diffusion of the supernatant.
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state [9, 26]. Serial studies of complement components
in our patients with hypocomplementemic glomerulo-
nephritis do not suggest immune complex activation,
but instead point to C3 activation by this alternate
pathway.
Suppression of antibody response in an immune
complex disease by immunosuppressive drug therapy
should be reflected by improvement in clinical status
and relevant laboratory tests. The rise of complement
components to normal in patients with systemic lupus
erythematosus who were treated with adequate dosages
of steroids or with cyclophosphamide suggests that
drug therapy depressed immune complex formation in
this disease. Further support for the suppression of
immune complex formation is found in the tendency
for elevated anti-DNA titers to fall concurrent with
the rise in complement titers. In contrast to systemic
lupus erythematosus, the failure of CH50 and C3 levels
to rise significantly in patients with hypocomple-
mentemic glomerulonephritis after courses of intensive
immunosuppressive therapy suggests that immune
complex formation is not a factor in the pathogenesis
of this disease.
The decreased specific activity of Cl (Cl/Clq and
Ci/Cis ratios) in patients with lupus erythematosus
may be influenced by Cl-inhibitor. The concentration
of inhibitor, although increased in some sera (Table 2),
was not consistently elevated or depressed, but the
concentration of inhibitor relative to the concentration
of Cl was increased (Table 3). A similar increase of
the Cl-inhibitor/Cl ratio has been described in
rheumatoid synovial fluids with low CH50 levels [27].
An in vitro model, in which BSA-anti-BSA complexes
are incubated with normal serum, showed depletion
of Clq, Cis, C4 and C3 without decrease in inhibitor
protein concentration, it is proposed that the increased
Cl-inhibitor/Cl ratio in the serum of children with
systemic lupus erythematosus is an indication of
immune complex activation and the consumption of
Cl. The absolute concentrations of Cl and Cl-inhibi-
tor, and the ratio of Cl-inhibitor/Cl, were normal in
children with hypocomplementemic glomerulonephri-
tis, thus supporting the thesis that the alternate path-
way is activated in this syndrome.
The complement profile with selective lowering of
C2 and C3 in a child with hypocomplementemic
glomerulonephritis has not been described previously.
Possible explanations for depressed C2 include:
decreased synthesis or the presence of a specific
inhibitor or inactivator. Hereditary C2-deficiency
unassociated with disease [10] and nonfamilial C2-
deficiency in a child with membranous glomerulo-
nephritis [28] have both been documented. In order
to determine whether our patient represented an
example of hereditary C2-deficiency who inadvertently
developed hypocomplementemic glomerulonephritis,
C2 titers were done on all available family members,
6 siblings and the mother. Since hereditary C2-defi-
ciency is an autosomal recessive trait and heterozygous
individuals have moderately depressed C2 levels, the
finding of a normal C2 level in the mother was not
consistent with this form of deficiency. In view of the
failure of the C2 and C3-deficient serum of our patient
to inactivate C2 or C3 in normal serum, the presence
of an inhibitor or inactivator seems unlikely. In fact
depression of C2 to less than one-third of normal
(390 SFU) in a healthy brother of the proband does
suggest a congenital basis other than the previously
described hereditary pattern of deficiency. Theoreti-
cally, the congenital absence of C2 could block the
activation of C3 by the conventional pathway and
provide evidence for the alternate pathway of C3
activation in hypocomplementemic glomerulonephritis.
Immune adherence, a function of C3b, is normal even
in the presence of marked C2-deficiency [14]. In this
setting, minimal quantities of C2 may activate C3
through C3-convertase in the classical pathway, or
C3b may be generated by the activation of C3-pro-
activator in the alternate pathway.
The child described previously with glomerulone-
phritis and C2-deficiency had membranous glomerulo-
nephritis, a definitive pathologic entity, and normal
serum C3 [28]. However, the development of gb-
merulonephritis, albeit of different types, in two C2-
deficient children, raises the interesting query: do
congenital complement abnormalities predispose to
the development of glomerular disease?
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